HLS Current Deferred Revenue from 2010 to 2026
| HLS Stock | CAD 4.65 0.05 1.06% |
Current Deferred Revenue | First Reported 1998-12-31 | Previous Quarter 6.2 M | Current Value 7.2 M | Quarterly Volatility 3.1 M |
Check HLS Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HLS Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 13.2 M, Interest Expense of 12.2 M or Total Revenue of 55.7 M, as well as many indicators such as Price To Sales Ratio of 1.19, Dividend Yield of 0.0102 or PTB Ratio of 0.73. HLS financial statements analysis is a perfect complement when working with HLS Therapeutics Valuation or Volatility modules.
HLS | Current Deferred Revenue |
Latest HLS Therapeutics' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of HLS Therapeutics over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. HLS Therapeutics' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in HLS Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
HLS Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 5,581,973 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 39.77 | |
| Mean Deviation | 1,460,928 | |
| Median | 6,560,750 | |
| Standard Deviation | 2,220,067 | |
| Sample Variance | 4.9T | |
| Range | 6.9M | |
| R-Value | 0.40 | |
| Mean Square Error | 4.4T | |
| R-Squared | 0.16 | |
| Significance | 0.11 | |
| Slope | 174,742 | |
| Total Sum of Squares | 78.9T |
HLS Current Deferred Revenue History
About HLS Therapeutics Financial Statements
HLS Therapeutics investors utilize fundamental indicators, such as Current Deferred Revenue, to predict how HLS Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 6.6 M | 6.9 M |
Other Information on Investing in HLS Stock
HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.